New York University has teamed up with corporate-backed biopharmaceutical incubator Futurx to spawn neurodegenerative disease drug developer Glixogen Therapeutics.

The university has helped launch 223 businesses, including 130 based on its IP, since an overhaul of its commercialisation strategy in 2013.

Immunooncology spinout Neoleukin Therapeutics is working on a safer, synthetic replica of a T-cell-boosting protein called interleukin-2.

ETH Zurich spinouts lifted their total funding haul to $173.3m from $123.1m in 2017.

University of Chicago’s Polsky Center for Entrepreneurship has formed microbiome-focused Avnovum Therapeutics, BiomeSense, Covira and Oxalo Therapeutics over the past year.

Industrial analytics spinout Mondas is targeting energy applications and has already started testing at a local solar energy network.

Newly-launched Bern University of Applied Sciences spinout Threatray believes its automated malware detection design will improve upon existing approaches.

ICL-founded Accunea hopes to commercialise a medical device enabling clinicians to catch acute kidney injuries earlier than currently possible.

Asgard Therapeutics will develop cancer therapies which use reprogrammed human skin cells to improve the immune system’s capacity to identify cancerous particles.

Next Offset Solutions will commercialise a 3D printing technology for energetic materials including rocket fuels and pyrotechnics.